Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza

May 14, 2020Cell

The outbreak of the coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has infected more than 100,000 people worldwide with over 3,000 deaths since December 2019. There is no cure for COVID-19 and the vaccine development is estimated to require 12-18 months. 

Download PDF

Durable multitransgene expression in vivo using systemic, nonviral DNA delivery

Mar 20, 2020Sciences Advances

Recombinant adeno-associated virus (AAV) vectors are transforming therapies for rare human monogenic deficiency diseases. However, adaptive immune responses to AAV and its limited DNA insert capacity, restrict their therapeutic potential. 

Read More

DNARx Awarded DARPA Contract for up to $10.7 Million to Develop Non-Viral DNA-Encoded Gene Therapy to Protect Against Pandemic Influenza

Aug 7, 2019GLOBE NEWSWIRE

DNARx’s proprietary HEDGES™ non-viral gene therapy delivery platform promises rapid, reliable, low-cost and relatively simple manufacturing and delivery of gene vectors to treat a wide range of diseases, particularly as compared to currently-employed delivery of genes using viruses.

Read More